NetraMark Holdings Inc. announced the launch of its NetraAI Lab offering, which is designed to make it easier and more affordable than ever for biopharmaceutical companies to experience the benefits of how its NetraAI solution can improve clinical trial success rates. Through this offering, NetraMark will apply NetraAI to customers' clinical trial data and seek to identify key variables that drive specific trial outcomes, provide testable hypotheses about the role that these variables play in patient responses and recommend inclusion and exclusion criteria based on these insights that can potentially be used to improve the success of future clinical trials. Customers participating in the offering will receive these valuable deliverables in only four weeks.

Key features and benefits of the NetraAI Lab include: NetraAl analysis for a single clinical stage asset; Defined categories of inquiry (e.g. response, placebo, toxicity); Dataset/data sources discovery (auditing /inventory); Next phase study simulation with regards to effect size and p-values; Four-week turnaround; Integrated project team; NetraAl project lead, senior data scientist, bioinformatician, clinical scientist; Sponsor development team; High-value deliverables/recommendations; Mid-stage meeting with initial findings and hypotheses testing; Final recommendations meeting; Presentation with detailed variables and simulation impact on effect size/p-values; Enrichment strategies and protocol design considerations. In contrast with other AI-based clinical trial solutions, NetraAI is uniquely engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved.

The NetraAI uses the explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses, as well as adverse events) that can increase the chances of a clinical trial success. Typical AI methods lack these focus mechanisms and assign every patient to a class, even when this leads to ?overfitting? which drowns out critical information that could be used to improve a trial's chance of success.

Additionally, the ?black box? approach of other AI solutions makes it difficult to understand the recommendations provided. In contrast, NetraAI is a ?glass house?

in which every variable identified is associated with a biologic rationale and testable hypothesis that customers' subject matter experts can evaluate and assess. The power of NetraAI has been validated in a recent publication in Frontiers in Computational Neuroscience, which described its use in discovering novel amyotrophic lateral sclerosis (ALS) drug targets and unique ALS patient subpopulations that may substantially improve clinical trial success rates. By launching the NetraAI Lab offering, NetraMark is of the view that participants will quickly see the value that NetraAI provides and ultimately adopt the NetraMark technology as a normal part of their clinical trial process.